Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: Results of a single-center, placebo-controlled trial

Annals of Allergy, Asthma and Immunology

Volumn 96, Issue 2, 2006, Pages 363-368

  Meltzer, Eli O ^a   Jalowayski, Alfredo A ^b   Vogt, Klaus ^c   Iezzoni, Domenic ^d   Harris, Alan G ^d  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c HNO Tagesklinik im Provianthaus   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESLORATADINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HAY FEVER; HEADACHE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NIGHT; NOSE AIRFLOW; NOSE SECRETION; OTITIS MEDIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOMANOMETRY; SCORING SYSTEM; SYMPTOM; URTICARIA;

EID: 33244466768     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61249-5     Document Type: Article

References (21)

1. Bousquet J, Van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(suppl): S147-S334.
2. Gentile DA, Friday GA, Skoner DP. Management of allergic rhinitis: antihistamines and decongestants. Immunol Allergy Clin North Am. 2000;20:355-368.
3. Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002;449:229-237.
4. Kreutner W, Hey JA, Anthes J, et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung. 2000;50:345-352.
5. Meltzer EO, Prenner BM, Nayak A; Desloratadine Study Group. Efficacy and tolerability of once-daily desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest. 2001;21:25-32.
6. Simons FE, Prenner BM, Finn A Jr; Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003;111:617-622.
7. Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2003;48:535-541.
8. Schenkel E, Corren J, Murray JJ. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc. 2002;23:325-330.
9. Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Fam Pract. 2002;3:14.
10. Berger WE, Schenkel EJ, Mansfield LE; Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol. 2002;89:485-491.
11. Horak F, Stubner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy. 2003;58:481-485.
12. Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002;109:956-961.
13. Vogt K, Sachse D, Wernecke KD, Kriesmer T. A computer-assisted system for diagnosing rhinologic function [in German]. HNO. 1990;38:110-115.
14. Vogt KFH, Hasse W. The clinical impact of high resolution rhinomanometry (HRR): statistical analysis of 1417 cases. Clin Exp Allergy. 2001;31:1155.
15. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999;104(pt 1):364-369.
16. Glesson MD, Youlten LJF, Shelton DM, Siodlak MZ, Eiser NM, Wengraf CL. Assessment of nasal airway patency: a comparison of four methods. Clin Otolaryngol. 1986;11:99-107.
17. Eccles R. Menthol: effects on nasal sensation of airflow and the drive to breathe. Curr Allergy Asthma Rep. 2003;3:210-214.
18. Hirschberg A, Rezek O. Correlation between objective and subjective assessments of nasal patency. ORL J Otorhinolaryngol Relat Spec. 1998;60:206-211.
19. Yaniv E, Hadar T, Shvero J, Raveh E. Objective and subjective nasal airflow. Am J Otolaryngol. 1997;18:29-32.
20. Simola H, Malberg M. Sensation of nasal airflow compared with nasal airway resistance in patients with rhinitis. Clin Otolaryngol. 1997;22:260-262.
21. Clarke RW, Cook JA, Jones AS. The effect of nasal mucosal vasoconstriction on nasal airflow sensation. Clin Otolaryngol. 1995;20:72-73.